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Abstract
Background: Metoclopramide is a dopamine D2-receptor antagonist used as an antiemetic and
gastroprokinetic agent in man and animals. The drug causes sedation as a side effect in man. Such
a sedative action of metoclopramide has not been documented in the chicken as the drug is not
used clinically in this species. The present study examines the central nervous system depressant
effects of metoclopramide in 7–14 days old broiler chicks.
Results: Injection of metoclopramide at 50, 100 and 200 mg/kg, subcutaneously (s.c.) induced
sedation in the chicks in a dose dependent manner. The chicks manifested, within 3.6–19 minutes
of metoclopramide injection, signs of sedation characterized by drooping of the head and wings,
closed eyelids, reduced motility and decreased distress calls. The duration of sedation ranged
between 37.2 to 163.4 minutes. Metoclopramide at 100 and 200 mg/kg induced, within 12.2 and
6.2 minutes, sleep (loss of righting reflex) for 43.8 and 158.6 minutes, respectively. The median
effective doses of metoclopramide for induction of sedation and sleep in the chicks were 11 and
53 mg/kg, s.c., respectively. Lower doses of metoclopramide (5 and 10 mg/kg, s.c.) significantly
decreased the open-field activity of the chicks and increased the durations of their tonic immobility.
All treated-chicks recovered from the central nervous system depressant effect of metoclopramide
without any observable adverse effects.
Conclusion: The data suggest that metoclopramide induces central nervous system depression in
chicks, and the drug could have potential clinical applications as a sedative-hypnotic agent in avian
species not intended for human consumptions.
Background
Metoclopramide (methoxychloroprocainamide) is a
dopamine D2-receptor antagonist used as an antiemetic
and gastroprokinetic agent in man [1] as well as in dogs
[2-4] and cats [3-5]. The drug also has serotonergic effects
[6] and indirect parasympathomimetic activity [7,8].
Metoclopramide has been used experimentally in pigeons
as an antiemetic agent at 10, 20 and 40 mg/kg, body
weight [9]. Antidopaminergic drugs such as phenothi-
azine tranquilizers are known to induce a state of sedation
in different animal species, including the chicken
[3,4,10]. Metoclopramide treatment has been reported to
cause sedation in man [1,11,12]. Such a sedative action of
metoclopramide, though a side effect, has not been docu-
mented in the chicken as the drug is not used clinically in
this species. In this communication, we present the cen-
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tral nervous system (CNS) depressant activity of metoclo-
pramide in 7–14 days old broiler chicks. This age group of
the chicken is suitable for examining sedative effects of
CNS depressants [13-15].
Results
Injection of metoclopramide at 50, 100 and 200 mg/kg,
subcutaneously (s.c.) induced sedation in the chicks in a
dose dependent manner. The chicks manifested within
3.6–19 minutes of metoclopramide injection (Table 1)
signs of sedation characterized by drooping of the head
and wings, closed eyelids, reduced motility and decreased
distress calls. The duration of sedation ranged between
37.2 to 163.4 minutes and it was also dose dependent
(Table 1). Metoclopramide at 100 and 200 mg/kg
induced, within 12.2 and 6.2 minutes, sleep (loss of right-
ing reflex) in the chicks for 43.8 and 158.6 minutes,
respectively (Table 1).
The median effective doses (ED50s) of metoclopramide
for the induction of sedation and sleep in the chicks, as
determined by the up-and-down method, were 11 and 53
mg/kg, s.c., respectively (Table 2). Metoclopramide at
lower doses (5 and 10 mg/kg, s.c.) also caused CNS
depression in chicks; the drug significantly decreased the
open field activity of the chicks and significantly increased
the durations of their tonic immobility (Table 3). All
chicks recovered smoothly from metoclopramide-
induced CNS depression and none of them suffered from
adverse effects or died during the study.
Table 1: Metoclopramide -induced sedation and sleep (loss of righting reflex) in chicks
Metoclopramide (mg/
kg, subcutaneously)
Latency to onset of 
sedation (minute)
Latency to onset of 
sleep (minute)
Duration of sedation 
(minute)




50 19.0 ± 2.2 none 37.2 ± 7.6 none 43.4 ± 7.8
100 8.8 ± 2.5* 12.2 ± 2.2 66.4 ± 5.5* 43.8 ± 3.5 74.6 ± 6.4*
200 3.6 ± 0.5* 6.2 ± 0.5† 163.4 ± 17.4*† 158.6 ± 23.3*† 168.4 ± 16.6*†
Values are mean ± SE of 5 chicks/group.
* Significantly different from the 50 mg/kg treatment group, P < 0.05.
† Significantly different from the 100 mg/kg treatment group, P < 0.05.
A control group of chicks was also treated with physiological saline solution (5 ml/kg, subcutaneously).
Table 2: Determination of median effective doses (ED50) of metoclopramide for induction of sedation and sleep (loss of righting 
reflex) in chicks by the up-and-down method*
Variable Result
Sedation
ED50 11 mg/kg, subcutaneously (s.c.)
Range of the doses used 25-5 = 20 mg/kg, s.c.
Initial dose 25 mg/kg, s.c.
Last dose 10 mg/kg, s.c.
Number of chicks used 8 (XXXXOOXO)
Increase or decrease in the dose 5 mg/kg, s.c.
Range of latency to induce sedation 20-5 = 15 minutes
Range of duration of sedation 44-7 = 37 minutes
Sleep
ED50 53 mg/kg, s.c.
Range of the doses used 100-50 = 50 mg/kg, s.c.
Initial dose 100 mg/kg, s.c.
Last dose 60 mg/kg, s.c.
Number of chicks used 9 (XXXXXOXOX)
Increase or decrease in the dose 10 mg/kg, s.c.
Range of latency to induce sleep 12-2 = 10 minutes
Range of duration of sleep 67-11 = 56 minutes
*Dixon [18].
X = sedation or sleep; O = no sedation or sleepBMC Veterinary Research 2005, 1:6 http://www.biomedcentral.com/1746-6148/1/6
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Discussion
Sedation has been reported clinically in man treated with
regular therapeutic (or higher) doses of metoclopramide
[1,11,12]. This effect has not been quantitatively reported
in animals, especially in avian species. In the present
report, metoclopramide -induced CNS depression in the
chicks was concluded depending on the signs of sedation
and sleep described in avian species [13-15]. The dura-
tions of sedation and sleep were also quantitatively
reported (Table 1). The ED50s of metoclopramide for the
induction of sedation and sleep were calculated for the
first time in chicks by the up-and down method. Open-
field activity and tonic immobility tests presented addi-
tional evidences for the CNS depressant activity of meto-
clopramide in the chicks. Little information are available
on the pharmacological profile of metoclopramide in
birds. The drug affects gastrointestinal motility in hispani-
olan parrots [16] and prevents reserpine-induced emesis
in pigeons [9]. Further, metoclopramide was found to
increase gastrointestinal tract motility and inhibit plasma
cholinesterase activity in chicks [17]. These effects are sim-
ilar to those found in other animal species [2-5,8] and fur-
ther suggest that the sedative activity of metoclopramide
in the chicken should be potentially expected.
Metoclopramide depression is usually considered a side
effect in man [1,11,12] and possibly in animals. Sedation
could then be an additional pharmacological (side) effect
of this drug to be expected in avian species. Further explo-
ration of the potential research and possibly therapeutic
applications of this drug is needed as a sedative agent in
avian species not intended for human consumption, as
the drug is not approved for use in food producing ani-
mals. The chicks in the present study were successfully
used as a model to show the CNS depressant action of
metoclopramide. Chicks were reported to be a suitable
animal model for examining the CNS depressant action of
drugs [13-15]. The sedative-hypnotic doses (50, 100 and
200 mg/kg, s.c.) of metoclopramide used in the present
study are higher than the therapeutic ones used in dogs
and cats [2-5]. However, the doses (especially the ED50s)
of metoclopramide used in the present study are close to
its antiemetic ones (10, 20 and 40 mg/kg, body weight,
orally) used in pigeons treated with reserpine [9]. Using
the open-field activity test, metoclopramide-induced CNS
depression could be detected in the present study even at
a dose as low as 5 mg/kg, s.c. (Table 3). Further, species
differences in the magnitude of response to metoclopra-
mide doses or its quality should be expected between
mammals and birds or even among various avian species.
Such a species difference has been reported with sedatives
like xylazine [4,10,15].
Overall, the findings of the present study indicate the sed-
ative and hypnotic (CNS depressant) effects of metoclo-
pramide in chicks. These effects could be attributed to the
antidopaminergic action of metoclopramide at the level
of the CNS [1]. Centrally acting antidopaminergic drugs
such as phenothiazine derivatives and butyrophenones
are known to induce CNS depression in different animals
as well as in avian species [3,4,10].
Conclusion
The data suggest that metoclopramide induces CNS
depression in chicks, and the drug could have potential
research and clinical applications as a sedative-hypnotic
agent in avian species not intended for human consump-
tion.
Methods
Unsexed, 7–14 days old, broiler chicks (body weight 52–
95 g) were used. They were maintained in batches of 20–
30 chicks at a time in a room at a temperature of 30–
34°C-controlled by electric heaters with constant lighting.
Litter consisted of wood shavings. Water and feed were
given ad libitum. The chicks were treated s.c. with physio-
logical saline solution at 5 ml/kg body weight (control
group) or with metoclopramide HCl (Yuhan Corp., South
Korea) at 50, 100 and 200 mg/kg body weight. Metoclo-
pramide was dissolved in physiological saline solution,
and the volume of administration was at 5 ml/kg body
weight. The site of s.c. injection was on either lateral side
of the chest. Care was taken so that leakage did not occur
during or after the drug administration from the site of
injection. The choice of metoclopramide doses was based
on preliminary experiments in chicks in which doses
Table 3: Effect of metoclopramide on open-field activity and tonic immobility test in chicks
Metoclopramide (mg/kg, subcutaneously) Squares crossed/5 minutes Duration of immobility (second)
0 (saline-control) 3.5 ± 1.4 10.5 ± 2.7
5 1.0 ± 1.0* 54.9 ± 18.1
10 0.1 ± 0.1* 130.6 ± 26.3*†
Open-field activity was measured 20 min after drug administration. Tonic immobility test was done immediately after the open-field test.
Values are mean ± SE of 8 chicks/group.
* Significantly different from the respective control values, P < 0.05.
† Significantly different from the 5 mg/kg treatment group, P < 0.05.BMC Veterinary Research 2005, 1:6 http://www.biomedcentral.com/1746-6148/1/6
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more than 20 mg/kg, s.c. induced signs of sedation char-
acterized by drooping of the head, closed eyelids, reduced
motility or immotility, and decreased distress calls as well
as recumbeny. After the injection of metoclopramide the
chicks were monitored for the onset of sedation (droop-
ing of the head) and sleep (loss of righting reflex after
placing the chick on one side). The durations of sedation
and sleep as well as recovery times were recorded too.
Recovery time was the time from the onset of sedation
until the chick moved freely. The ED50s of metoclopra-
mide for the induction of sedation or sleep in the chicks
were determined by the up-and-down method [18].
Further, the CNS depressant action of metoclopramide at
lower doses (5 and 10 mg/kg) was also monitored by
examining the open field activity [13,19] of the chicks and
then subjecting them to the tonic immobility test [20]. In
this experiment the chicks were treated s.c. with either
physiological saline solution (control) at 5 ml/kg, or with
metoclopramide at 5 and 10 mg/5 ml saline/kg body
weight. Twenty minutes after the injection, each chick was
placed alone on the center of the arena of an open field
box (90 × 60 × 50 cm); the arena was divided into 24
equal squares and 50 g of wheat grains were scattered on
the surface [13]. Open field activity was monitored by
counting, within 5 minutes, the number of squares
entered by both feet. After the open field activity test, each
chick was subjected to tonic immobility test [20] by hold-
ing the chick in both hands and placing it on a wooden
table for 15 seconds, then the hands were withdrawn and
the chick was timed to upright itself and standing.
All experiments complied with regulations addressing
animal use, and proper attention has been given to ethical
consideration towards the chicks used in the present
study. The data were statistically analyzed by one way
analysis of variance followed by the least significant differ-
ence test [21]. Non-parametric data (open-field activity)
were subjected to Mann-Whitney-U-test [22]. The level of
significance was at P < 0.05.
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